All In Biotech

Drug Trial Radar · NCT05083364

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and/or Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Complement-Mediated Renal Disease

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

62

Actual

Start

Feb 1, 2022

Primary completion

Sep 10, 2025

Study completion Sep 10, 2025

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patients with complement-mediated renal disease (C3 Glomerulopathy \[C3G\] and IgA Nephropathy \[IgAN\]). In Part 1 of the study, HVs will receive either one or two doses of ARO-C3 or placebo. In Part 2 of the study, adult patients with C3G/IgAN will receive 3 open-label doses of ARO-C3. Dose levels in Part 2 will be determined based on cumulative safety and pharmacodynamic data from Part 1.

Conditions

  • C3 Glomerulopathy
  • IgA Nephropathy

Interventions

  • ARO-C3Drug

    ARO-C3 for sc injection

  • PlaceboDrug

    sterile normal saline (0.9% NaCl) for sc injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs) at Day 169Time frame: up to day 169 (End of Study [EOS])

Locations

16 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site 1

    Camperdown, New South Wales, Australia

  • Research Site 3

    Concord, New South Wales, Australia

  • Research Site 2

    Clayton, Victoria, Australia

  • Research Site 2

    Tbilisi, Georgia

  • Research Site 2

    Cologne, Germany

  • Research Site 4

    Erlangen, Germany

  • Research Site

    Auckland, New Zealand

  • Research Site 3

    Daegu, South Korea

  • Research Site 6

    Soeul, South Korea

  • Research Site 8

    Soeul, South Korea

  • Research Site 1

    Gamcheon, Busan, South Korea

  • Research Site 2

    Haeundae, Busan, South Korea

  • Research Site 4

    Goyang-si, Gyeonggi-do, South Korea

  • Research Site 2

    Bangkok, Thailand

  • Research Site 3

    Chiang Mai, Thailand

  • Research Site 4

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.